148 related articles for article (PubMed ID: 31848023)
1. Factors associated with long-term persistence of rituximab in rheumatoid arthritis In clinical practice: RITAR Study.
Cañamares Orbis I; Merino Meléndez L; Llorente Cubas I; Benedí González J; García-Vicuña R; Morell Baladrón A; González-Álvaro I; Ramírez Herraiz E
Med Clin (Barc); 2020 Jul; 155(1):1-8. PubMed ID: 31848023
[TBL] [Abstract][Full Text] [Related]
2. Eficiency of different doses of rituximab in rheumatoid arthritis.
Mena-Vázquez N; Manrique-Arija S; Ureña-Garnica I; Romero-Barco CM; Jiménez-Núñez FG; Coret V; Irigoyen-Oyarzábal MV; Fernández-Nebro A
Reumatol Clin; 2016; 12(3):139-45. PubMed ID: 26458761
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
[TBL] [Abstract][Full Text] [Related]
4. Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration.
Chatzidionysiou K; Lie E; Lukina G; Hetland ML; Hauge EM; Pavelka K; Gabay C; Scherer A; Nordström D; Canhao H; Santos MJ; Tomsic M; Rotar Z; Hernández MV; Gomez-Reino J; Ancuta I; Kvien TK; van Vollenhoven R
J Rheumatol; 2017 Feb; 44(2):162-169. PubMed ID: 28089978
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of rituximab in resistant palindromic rheumatism: first report in literature.
Raghavan P; Sreenath S; Cherian S; Shenoy PD
Clin Rheumatol; 2019 Sep; 38(9):2399-2402. PubMed ID: 31076945
[TBL] [Abstract][Full Text] [Related]
6. Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020.
Norris-Grey C; Cambridge G; Moore S; Reddy V; Leandro M
Rheumatology (Oxford); 2022 Feb; 61(2):591-596. PubMed ID: 33769451
[TBL] [Abstract][Full Text] [Related]
7. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry.
De Keyser F; Hoffman I; Durez P; Kaiser MJ; Westhovens R;
J Rheumatol; 2014 Sep; 41(9):1761-5. PubMed ID: 25128506
[TBL] [Abstract][Full Text] [Related]
8. Sustainability of rituximab therapy in different treatment strategies: results of a 3-year followup of a German biologics register.
Richter A; Strangfeld A; Herzer P; Wilden E; Bussmann A; Listing J; Zink A
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1627-33. PubMed ID: 24664818
[TBL] [Abstract][Full Text] [Related]
9. Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial.
den Broeder N; Verhoef L; de Man YA; Kok MR; Thurlings R; van der Weele W; van den Bemt BJ; van den Hoogen FH; van der Maas A; den Broeder AA
RMD Open; 2024 Apr; 10(2):. PubMed ID: 38599654
[TBL] [Abstract][Full Text] [Related]
10. Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis.
Melville AR; Md Yusof MY; Fitton J; Garcia-Montoya L; Bailey L; Dass S; Emery P; Buch MH; Saleem B
Rheumatology (Oxford); 2021 Aug; 60(8):3679-3688. PubMed ID: 33432358
[TBL] [Abstract][Full Text] [Related]
11. Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab.
Łosińska K; Korkosz M; Pripp AH; Haugeberg G
Rheumatol Int; 2023 May; 43(5):881-888. PubMed ID: 36922417
[TBL] [Abstract][Full Text] [Related]
12. VARIAR Study: Assessment of short-term efficacy and safety of rituximab compared to an tumor necrosis factor alpha antagonists as second-line drug therapy in patients with rheumatoid arthritis refractory to a first tumor necrosis factor alpha antagonist.
Torrente-Segarra V; Acosta Pereira A; Morla R; Ruiz JM; Clavaguera T; Figuls R; Corominas H; Geli C; Roselló R; de Agustín JJ; Alegre C; Pérez C; García A; Rodríguez de la Serna A
Reumatol Clin; 2016; 12(6):319-322. PubMed ID: 26831256
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients.
Wendler J; Burmester GR; Sörensen H; Krause A; Richter C; Tony HP; Rubbert-Roth A; Bartz-Bazzanella P; Wassenberg S; Haug-Rost I; Dörner T
Arthritis Res Ther; 2014 Mar; 16(2):R80. PubMed ID: 24670196
[TBL] [Abstract][Full Text] [Related]
14. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge EM; Pavelka K; Nordström DC; Canhão H; Tomšič M; van Vollenhoven R; Gabay C
Rheumatology (Oxford); 2016 Feb; 55(2):230-6. PubMed ID: 26316581
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
Smolen JS; Cohen SB; Tony HP; Scheinberg M; Kivitz A; Balanescu A; Gomez-Reino J; Cen L; Poetzl J; Shisha T; Kollins D
Rheumatology (Oxford); 2021 Jan; 60(1):256-262. PubMed ID: 32699904
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in routine care of severe active rheumatoid arthritis : A prospective, non-interventional study in Germany.
Krause A; Aries PM; Berger S; Fiehn C; Kellner H; Lorenz HM; Meier L; Müller GA; Müller-Ladner U; Schwarting A; Tony HP; Peters MA; Wendler J
Z Rheumatol; 2019 Nov; 78(9):881-888. PubMed ID: 30276727
[TBL] [Abstract][Full Text] [Related]
17. Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection.
Henry J; Gottenberg JE; Rouanet S; Pavy S; Sellam J; Tubach F; Belkhir R; Mariette X; Seror R;
Rheumatology (Oxford); 2018 Mar; 57(3):538-547. PubMed ID: 29267905
[TBL] [Abstract][Full Text] [Related]
18. Long-term real-life experience with rituximab in adult Finnish patients with rheumatoid arthritis refractory or with contraindication to anti-tumor necrosis factor drugs.
Valleala H; Korpela M; Hienonen-Kempas T; Immonen K; Lähteenmäki J; Uusitalo T; Komulainen R; Möttönen T; Hannonen P
J Clin Rheumatol; 2015 Jan; 21(1):24-30. PubMed ID: 25539430
[TBL] [Abstract][Full Text] [Related]
19. Long-term persistence with rituximab in patients with rheumatoid arthritis.
Oldroyd AGS; Symmons DPM; Sergeant JC; Kearsley-Fleet L; Watson K; Lunt M; Hyrich KL;
Rheumatology (Oxford); 2018 Jun; 57(6):1089-1096. PubMed ID: 29566213
[TBL] [Abstract][Full Text] [Related]
20. Experience With the Use of Rituximab for the Treatment of Rheumatoid Arthritis in a Tertiary Hospital in Spain: RITAR Study.
Cañamares I; Merino L; López J; Llorente I; García-Vadillo A; Ramirez E; López-Bote JP; Benedí J; Muñoz-Calleja C; Álvaro-Gracia JM; Castañeda S; González-Álvaro I
J Clin Rheumatol; 2019 Sep; 25(6):258-263. PubMed ID: 30001257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
